Naoko Takebe to Mutation
This is a "connection" page, showing publications Naoko Takebe has written about Mutation.
Connection Strength
1.151
-
Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G. Oncologist. 2024 Aug 05; 29(8):723-e1093.
Score: 0.179
-
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors. Clin Cancer Res. 2024 May 01; 30(9):1739-1749.
Score: 0.175
-
Methotrexate selection of long-term culture initiating cells following transduction of CD34(+) cells with a retrovirus containing a mutated human dihydrofolate reductase gene. Cancer Gene Ther. 2002 Mar; 9(3):308-20.
Score: 0.151
-
Generation of dual resistance to 4-hydroperoxycyclophosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated dihydrofolate reductase gene. Mol Ther. 2001 Jan; 3(1):88-96.
Score: 0.139
-
Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903). Clin Cancer Res. 2021 03 15; 27(6):1604-1611.
Score: 0.139
-
Considerations of developing an NGS assay for clinical applications in precision oncology: The NCI-MATCH NGS assay experience. Curr Probl Cancer. 2017 May - Jun; 41(3):201-211.
Score: 0.108
-
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer Res Commun. 2024 07 01; 4(7):1793-1801.
Score: 0.044
-
Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. J Clin Oncol. 2022 07 10; 40(20):2224-2234.
Score: 0.038
-
The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study. J Natl Cancer Inst. 2021 01 04; 113(1):27-37.
Score: 0.035
-
Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH. Curr Probl Cancer. 2017 May - Jun; 41(3):182-193.
Score: 0.027
-
Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia. Leuk Lymphoma. 2015; 56(12):3336-42.
Score: 0.024
-
A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients. Invest New Drugs. 2014 Oct; 32(5):1005-16.
Score: 0.022
-
KIT as a therapeutic target in metastatic melanoma. JAMA. 2011 Jun 08; 305(22):2327-34.
Score: 0.018
-
Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010 Oct 20; 28(30):4609-15.
Score: 0.017
-
Protection of hematopoietic stem cells from pemetrexed toxicity by retroviral gene transfer with a mutant dihydrofolate reductase-mutant thymidylate synthase fusion gene. Cancer Gene Ther. 2004 Dec; 11(12):767-73.
Score: 0.011
-
Retroviral transduction of a mutant dihydrofolate reductase-thymidylate synthase fusion gene into murine marrow cells confers resistance to both methotrexate and 5-fluorouracil. Hum Gene Ther. 2003 Mar 20; 14(5):435-46.
Score: 0.010
-
Protection of bone marrow cells from toxicity of chemotherapeutic agents targeted toward thymidylate synthase by transfer of mutant forms of human thymidylate synthase cDNA. Prog Exp Tumor Res. 1999; 36:107-14.
Score: 0.008
-
Co-expression of the herpes simplex virus thymidine kinase gene potentiates methotrexate resistance conferred by transfer of a mutated dihydrofolate reductase gene. Gene Ther. 1997 Jun; 4(6):570-6.
Score: 0.007